Nuvectis Pharma (NASDAQ:NVCT) Director Matthew Kaplan Buys 11,000 Shares

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Director Matthew Kaplan bought 11,000 shares of Nuvectis Pharma stock in a transaction on Wednesday, November 5th. The shares were bought at an average cost of $5.84 per share, with a total value of $64,240.00. Following the acquisition, the director directly owned 124,760 shares in the company, valued at approximately $728,598.40. This represents a 9.67% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Nuvectis Pharma Trading Up 2.5%

Shares of Nuvectis Pharma stock traded up $0.14 on Friday, reaching $5.81. The stock had a trading volume of 14,766 shares, compared to its average volume of 131,043. The business’s 50 day moving average is $6.21 and its two-hundred day moving average is $7.54. Nuvectis Pharma, Inc. has a 1 year low of $4.44 and a 1 year high of $11.80. The company has a market cap of $148.79 million, a P/E ratio of -4.22 and a beta of -0.28.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.20). On average, equities analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NVCT. Goldman Sachs Group Inc. purchased a new position in Nuvectis Pharma in the 1st quarter worth $446,000. Iridian Asset Management LLC CT purchased a new stake in Nuvectis Pharma during the 1st quarter valued at about $2,481,000. OMERS ADMINISTRATION Corp bought a new position in Nuvectis Pharma during the 1st quarter worth approximately $321,000. Austin Wealth Management LLC bought a new stake in Nuvectis Pharma in the first quarter valued at approximately $393,000. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Nuvectis Pharma during the second quarter valued at approximately $28,000. 96.77% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on NVCT shares. Weiss Ratings restated a “sell (e+)” rating on shares of Nuvectis Pharma in a research note on Wednesday, October 8th. HC Wainwright decreased their price objective on shares of Nuvectis Pharma from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, August 4th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.33.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.